Geron Corporation published a document on outcomes of imetelstat therapy in patients with ring sideroblast-negative lower-risk myelodysplastic syndromes from the pooled Imerge study populations. The document provides insights into the limited treatment options available for lower-risk myelodysplastic syndromes, particularly for patients ineligible for erythropoiesis-stimulating agents or whose disease is relapsed or refractory to these agents. The full document can be accessed through the link below.